Back to School: How biopharma can reboot drug development. Access exclusive analysis here

0910 BTS50 Bilenker podcast
BioCentury & Getty Images

Back to School 2020

Loxo’s Bilenker on why reimbursement crisis is creating innovation, access crises: a BioCentury audio interview

Bilenker: false choice between affordable healthcare and cutting-edge medicines creates crises in antimicrobial resistance and diagnostics

Loxo’s Josh Bilenker says the false choice between affordable healthcare and cutting-edge medicines creates crises in antimicrobial resistance and diagnostics. 

Sep 11, 2020 | 2:53 AM GMT

COVID-19 has spotlighted the critical role of diagnostics and focused the world’s attention on the threats posed by infectious pathogens. Awareness is good, but what’s really needed to advance diagnostics and antibiotics are reimbursement models that incentivize innovation,  says Josh Bilenker, CEO of the Loxo Oncology at Lilly.

Bilenker spoke to BioCentury as part of the series of audio interviews with industry leaders for the 2020 Back to School package (see Cover Story: “The Imperative of COVID-19”).

Bilenker founded Loxo in 2013. The company was acquired by Eli Lilly and Co. (NYSE:LLY) in 2019 and has become the pharma’s cancer discovery research and clinical development engine.

Bilenkar thinks the drug pricing issue will surface again after COVID, but that the discussion needs to go beyond the “false choice” in which it’s currently framed.

“It’s impossible to argue that the pricing

Read the full 2000 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE